Dexcom (Nasdaq:DXCM) today filed an SEC form to announce that Chair and CEO Kevin Sayer is taking a temporary medical leave of absence.
Our sister site, Drug Delivery Business News, reports today that Sayer’s leave went into effect on Sept. 14, 2025. The Dexcom board appointed Jake Leach to serve as interim principal executive officer, in addition to his current duties as president and COO. Leach has already been selected to take the role permanently at the start of 2026 as part of Dexcom’s planned succession process.
Leach has spent 21 years at the company, leading teams responsible for developing multiple generations of continuous glucose monitors CGMs. In 2022, Leach took over as COO at Dexcom, one of the largest diabetes tech companies in the world. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments.
Get the full story at our sister site, Drug Delivery Business News.
Dexcom’s CTO Girish Naganathan will speak about the future of connected health at DeviceTalks West, Oct. 15–16, 2025 in Santa Clara, California. Register at West.DeviceTalks.com.
